Patents by Inventor Seshidhar Reddy Police
Seshidhar Reddy Police has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240041757Abstract: Provided herein include compositions, methods and systems for delivery of CRISPR/Cas-mediated gene editing systems using lipid nanoparticles (LNP) to trabecular meshwork cells. Methods, compositions and systems for treating glaucoma are also provided herein, which involve reducing the expression of myocilin (MYOC) gene in the trabecular meshwork cells of patients' eyes.Type: ApplicationFiled: June 17, 2023Publication date: February 8, 2024Inventors: Seshidhar Reddy Police, Dominique Ouellet, Michael Lukason, Mary-Lee Dequeant
-
Publication number: 20240002843Abstract: The present invention is directed to genome editing systems, reagents and methods for the treatment of hemoglobinopathies.Type: ApplicationFiled: October 13, 2022Publication date: January 4, 2024Applicants: Novartis AG, Intellia Therapeutics, Inc.Inventors: Anthony Edward BOITANO, Michael COOKE, Lloyd B. KLICKSTEIN, Reynald LESCARBEAU, Craig Stephen MICKANIN, Kabungo MULUMBA, Seshidhar Reddy POLICE, Jennifer SNEAD, Susan C. STEVENSON, Morag STEWART, Yi YANG
-
Publication number: 20230323398Abstract: The present invention relates to viral vectors that are capable of delivering a heterologous gene to the retina and in particular delivering RLBP1 to RPE and Müller cells of the retina. The invention also relates nucleic acids useful for producing viral vectors, compositions comprising the viral vectors and uses of the compositions and viral vectors. The invention also relates to methods of delivering and/or expressing a heterologous gene to the retina, improving the rate of dark adaption in a subject and treating RLBP1-associated retinal dystrophy.Type: ApplicationFiled: January 26, 2023Publication date: October 12, 2023Inventors: Chad Eric BIGELOW, Vivian CHOI, Thaddeus Peter DRYJA, Akshata Ninad GUJAR, Shawn Michael HANKS, Terri MCGEE, Seshidhar Reddy POLICE, Joanna VROUVLIANIS
-
Publication number: 20230052011Abstract: Provided herein are regulatable expression systems and methods of using said regulatable expression systems to express proteins of interest. The regulatable expression systems comprise a unidirectional regulatable promoter operably linked to a single transcription unit encoding a protein of interest, a ribosome skip, and a transactivator protein.Type: ApplicationFiled: December 1, 2020Publication date: February 16, 2023Applicant: CRISPR THERAPEUTICS AGInventors: Seshidhar Reddy Police, Kyungah Maeng
-
Publication number: 20220056438Abstract: The disclosure provides systems (e.g., CRISPR/Cas systems) for introducing an edit in a genomic DNA molecule comprising the fatty acid amide hydrolase gene (FAAH) and/or the FAAH pseudogene (FAAH-OUT). Also provided are methods for use of the systems, nucleic acids, delivery systems, and/or compositions described for genome editing to modulate the expression and/or activity of FAAH, for example, in a method of treating chronic pain.Type: ApplicationFiled: August 20, 2021Publication date: February 24, 2022Inventors: Seshidhar Reddy Police, Tony Ho, Yanfei Yang, Hemangi Chaudhari, Anandan Paldurai
-
Publication number: 20210363521Abstract: The disclosure provides to CRISPR/Cas systems and compositions which target the dystrophin gene. Also provided are methods for using the CRISPR/Cas systems, vectors and compositions in methods for genome engineering to correct a mutant dystrophin gene, and for treating Duchenne muscular dystrophy.Type: ApplicationFiled: November 9, 2018Publication date: November 25, 2021Applicant: Vertex Pharmaceuticals IncorporatedInventors: Seshidhar Reddy Police, Song Chou, Thomas James Cradick, Robert Ng, Yanfei Yang
-
Publication number: 20210047656Abstract: The present invention relates to viral vectors that are capable of delivering a heterologous gene to the retina and in particular delivering RLBP1 to RPE and Müller cells of the retina. The invention also relates nucleic acids useful for producing viral vectors, compositions comprising the viral vectors and uses of the compositions and viral vectors. The invention also relates to methods of delivering and/or expressing a heterologous gene to the retina, improving the rate of dark adaption in a subject and treating RLBP1-associated retinal dystrophy.Type: ApplicationFiled: December 23, 2019Publication date: February 18, 2021Inventors: Vivian CHOI, Chad Eric BIGELOW, Thaddeus Peter DRYJA, Seshidhar Reddy POLICE
-
Publication number: 20210047649Abstract: The present disclosure provides materials and methods for treating a patient with Duchenne Muscular Dystrophy (DMD), e.g., through ex vivo and in vivo methods of genome editing. The present disclosure also relates to methods and compositions for use of self-inactivating/self-targeting CRISPR/Cas or CRISPR/Cpf1 systems to genetically modify cells, e.g., to modulate the expression, function, and/or activity of the dystrophin gene.Type: ApplicationFiled: May 8, 2020Publication date: February 18, 2021Applicant: Vertex Pharmaceuticals IncorporatedInventors: Robert NG, Seshidhar Reddy POLICE, Yanfei YANG
-
Publication number: 20210032622Abstract: The invention relates to self-inactivating/self-targeting CRISPR/Cas or CRISPR/Cpf1 systems. The invention also relates to genetically modified cells related to the same. The invention also relates to methods of controlling Cas9 expression in a cell related to the same. The invention also relates to methods of genetically modifying a cell related to the same. The invention also relates to nucleic acids for use in a self-inactivating CRISPR/Cas or CRISPR/Cpf1 system. The invention also relates to pharmaceutical compositions related to the same.Type: ApplicationFiled: November 9, 2018Publication date: February 4, 2021Inventors: Seshidhar Reddy POLICE, Song CHOU, Thomas James CRADICK, Robert NG
-
Patent number: 10550404Abstract: The present invention relates to viral vectors that are capable of delivering a heterologous gene to the retina and in particular delivering RLBP1 to RPE and Müller cells of the retina. The invention also relates nucleic acids useful for producing viral vectors, compositions comprising the viral vectors and uses of the compositions and viral vectors. The invention also relates to methods of delivering and/or expressing a heterologous gene to the retina, improving the rate of dark adaption in a subject and treating RLBP1-associated retinal dystrophy.Type: GrantFiled: September 22, 2017Date of Patent: February 4, 2020Assignee: NOVARTIS AGInventors: Vivian Choi, Chad Eric Bigelow, Thaddeus Peter Dryja, Seshidhar Reddy Police
-
Publication number: 20190010495Abstract: The present invention is directed to genome editing systems, reagents and methods for the treatment of hemoglobinopathies.Type: ApplicationFiled: December 26, 2016Publication date: January 10, 2019Applicants: NOVARTIS AG, INTELLIA THERAPEUTICS, INC.Inventors: Anthony Edward BOITANO, Michael COOKE, Lloyd B. KLICKSTEIN, Reynald LESCARBEAU, Craig Stephen MICKANIN, Kabungo MULUMBA, Seshidhar Reddy POLICE, Jennifer SNEAD, Susan C. STEVENSON, Morag STEWART, Yi YANG
-
Publication number: 20180080046Abstract: The present invention relates to viral vectors that are capable of delivering a heterologous gene to the retina and in particular delivering RLBP1 to RPE and Müller cells of the retina. The invention also relates nucleic acids useful for producing viral vectors, compositions comprising the viral vectors and uses of the compositions and viral vectors. The invention also relates to methods of delivering and/or expressing a heterologous gene to the retina, improving the rate of dark adaption in a subject and treating RLBP1-associated retinal dystrophy.Type: ApplicationFiled: September 22, 2017Publication date: March 22, 2018Applicant: Novartis AGInventors: Vivian CHOI, Chad Eric BIGELOW, Thaddeus Peter DRYJA, Seshidhar Reddy POLICE
-
Patent number: 9803217Abstract: The present invention relates to viral vectors that are capable of delivering a heterologous gene to the retina and in particular delivering RLBP1 to RPE and Müller cells of the retina. The invention also relates nucleic acids useful for producing viral vectors, compositions comprising the viral vectors and uses of the compositions and viral vectors. The invention also relates to methods of delivering and/or expressing a heterologous gene to the retina, improving the rate of dark adaption in a subject and treating RLBP1-associated retinal dystrophy.Type: GrantFiled: October 13, 2015Date of Patent: October 31, 2017Assignee: NOVARTIS AGInventors: Vivian Choi, Chad Eric Bigelow, Thaddeus Peter Dryja, Seshidhar Reddy Police
-
Publication number: 20160097061Abstract: The present invention relates to viral vectors that are capable of delivering a heterologous gene to the retina and in particular delivering RLBP1 to RPE and Müller cells of the retina. The invention also relates nucleic acids useful for producing viral vectors, compositions comprising the viral vectors and uses of the compositions and viral vectors. The invention also relates to methods of delivering and/or expressing a heterologous gene to the retina, improving the rate of dark adaption in a subject and treating RLBP1-associated retinal dystrophy.Type: ApplicationFiled: October 13, 2015Publication date: April 7, 2016Applicant: NOVARTIS AGInventors: Vivian CHOI, Chad Eric BIGELOW, Thaddeus Peter DRYJA, Seshidhar Reddy POLICE
-
Patent number: 9163259Abstract: The present invention relates to viral vectors that are capable of delivering a heterologous gene to the retina and in particular delivering RLBP1 to RPE and Müller cells of the retina. The invention also relates nucleic acids useful for producing viral vectors, compositions comprising the viral vectors and uses of the compositions and viral vectors. The invention also relates to methods of delivering and/or expressing a heterologous gene to the retina, improving the rate of dark adaption in a subject and treating RLBP1-associated retinal dystrophy.Type: GrantFiled: April 30, 2013Date of Patent: October 20, 2015Assignee: Novartis AGInventors: Vivian Choi, Chad Eric Bigelow, Thaddeus Peter Dryja, Seshidhar Reddy Police
-
Publication number: 20140348798Abstract: The present invention relates to a novel RNA picornavirus that is called Seneca Valley virus (“SVV”). The invention provides isolated SVV nucleic acids and proteins encoded by these nucleic acids. Further, the invention provides antibodies that are raised against the SVV proteins. Because SVV has the ability to selectively kill some types of tumors, the invention provides methods of using SVV and SVV polypeptides to treat cancer. Because SVV specifically targets certain tumors, the invention provides methods of using SVV nucleic acids and proteins to detect cancer. Additionally, due to the information provided by the tumor-specific mechanisms of SVV, the invention provides methods of making new oncolytic virus derivatives and of altering viruses to have tumor-specific tropisms.Type: ApplicationFiled: March 7, 2014Publication date: November 27, 2014Applicant: NOVARTIS AGInventors: Paul L. HALLENBECK, Seshidhar Reddy POLICE, Laura M. HALES, Carl M. HAY, Shanthi GANESH, Ling XU, Jingping YANG, Cheng CHENG
-
Patent number: 8753622Abstract: The present invention relates to a novel RNA picornavirus that is called Seneca Valley virus (“SVV”). The invention provides isolated SVV nucleic acids and proteins encoded by these nucleic acids. Further, the invention provides antibodies that are raised against the SVV proteins. Because SVV has the ability to selectively kill some types of tumors, the invention provides methods of using SVV and SVV polypeptides to treat cancer. Because SVV specifically targets certain tumors, the invention provides methods of using SVV nucleic acids and proteins to detect cancer. Additionally, due to the information provided by the tumor-specific mechanisms of SVV, the invention provides methods of making new oncolytic virus derivatives and of altering viruses to have tumor-specific tropisms.Type: GrantFiled: August 12, 2011Date of Patent: June 17, 2014Assignee: Novartis AGInventors: Paul Hallenbeck, Seshidhar Reddy Police, Laura M. Hales, Carl Hay, Shanthi Ganesh, Ling Xu, Jingping Yang, Cheng Cheng
-
Publication number: 20140017201Abstract: The present invention relates to viral vectors that are capable of delivering a heterologous gene to the retina and in particular delivering RLBP1 to RPE and Müller cells of the retina. The invention also relates nucleic acids useful for producing viral vectors, compositions comprising the viral vectors and uses of the compositions and viral vectors. The invention also relates to methods of delivering and/or expressing a heterologous gene to the retina, improving the rate of dark adaption in a subject and treating RLBP1-associated retinal dystrophy.Type: ApplicationFiled: April 30, 2013Publication date: January 16, 2014Applicant: NOVARTIS AGInventors: Vivian Choi, Chad Eric Bigelow, Thaddeus Peter Dryja, Seshidhar Reddy Police
-
Patent number: 8039606Abstract: The present invention relates to a novel RNA picornavirus that is called Seneca Valley virus (“SVV”). The invention provides isolated SVV nucleic acids and proteins encoded by these nucleic acids. Further, the invention provides antibodies that are raised against the SVV proteins. Because SVV has the ability to selectively kill some types of tumors, the invention provides methods of using SVV and SVV polypeptides to treat cancer. Because SVV specifically targets certain tumors, the invention provides methods of using SVV nucleic acids and proteins to detect cancer. Additionally, due to the information provided by the tumor-specific mechanisms of SVV, the invention provides methods of making new oncolytic virus derivatives and of altering viruses to have tumor-specific tropisms.Type: GrantFiled: October 9, 2009Date of Patent: October 18, 2011Assignee: Novartis AGInventors: Paul Hallenbeck, Seshidhar Reddy Police, Laura M. Hales, Carl Hay, Shanthi Ganesh, Ling Xu, Jingping Yang, Cheng Cheng
-
Publication number: 20100129325Abstract: The present invention relates to a novel RNA picornavirus that is called Seneca Valley virus (“SVV”). The invention provides isolated SVV nucleic acids and proteins encoded by these nucleic acids. Further, the invention provides antibodies that are raised against the SVV proteins. Because SVV has the ability to selectively kill some types of tumors, the invention provides methods of using SVV and SVV polypeptides to treat cancer. Because SVV specifically targets certain tumors, the invention provides methods of using SVV nucleic acids and proteins to detect cancer. Additionally, due to the information provided by the tumor-specific mechanisms of SVV, the invention provides methods of making new oncolytic virus derivatives and of altering viruses to have tumor-specific tropisms.Type: ApplicationFiled: October 9, 2009Publication date: May 27, 2010Applicant: NOVARTIS AGInventors: Paul L. HALLENBECK, Seshidhar Reddy POLICE, Laura M. HALES, Carl M. HAY, Shanthi GANESH, Ling XU, Jingping YANG, Cheng CHENG